These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 25733924

  • 1. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.
    Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC.
    Int J Gen Med; 2015; 8():79-86. PubMed ID: 25733924
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 3. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 5. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 6. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT, Jaffri SF.
    Headache; 2009 Jan; 49(10):1466-78. PubMed ID: 19912346
    [Abstract] [Full Text] [Related]

  • 7. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 9. Nefazodone for chronic daily headache prophylaxis: an open-label study.
    Saper JR, Lake AE, Tepper SJ.
    Headache; 2001 May 16; 41(5):465-74. PubMed ID: 11380644
    [Abstract] [Full Text] [Related]

  • 10. The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.
    Ilgaz Aydinlar E, Erdogan Soyukibar T, Yalinay Dikmen P.
    Front Neurol; 2024 May 16; 15():1417303. PubMed ID: 38962481
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 16; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 12. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
    Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S.
    BMC Neurol; 2015 Jul 03; 15():100. PubMed ID: 26133547
    [Abstract] [Full Text] [Related]

  • 13. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
    Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, D Silberstein S.
    J Neurol Neurosurg Psychiatry; 2019 Mar 03; 90(3):353-360. PubMed ID: 30630956
    [Abstract] [Full Text] [Related]

  • 14. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF.
    J Prim Care Community Health; 2020 Mar 03; 11():2150132720959936. PubMed ID: 32985341
    [Abstract] [Full Text] [Related]

  • 15. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.
    Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG, Gungen BD.
    Neurol Sci; 2016 Nov 03; 37(11):1779-1784. PubMed ID: 27418178
    [Abstract] [Full Text] [Related]

  • 16. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Jan 22; 20(1):10. PubMed ID: 30669961
    [Abstract] [Full Text] [Related]

  • 17. Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine Patients.
    Al-Hashel JY, Kh Ashkanani H, Almutairi O, Bokubar FA, Mubarak S, Alwazzan S, Alroughani R, Youssry D, Farouk Ahmed S.
    Front Neurol; 2020 Jan 22; 11():633355. PubMed ID: 33584525
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 19. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
    Artemenko AR, Abramov VG, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Yakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Aug 15; 123(5):89-99. PubMed ID: 37315247
    [Abstract] [Full Text] [Related]

  • 20. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU.
    Headache; 2011 Jan 15; 51(1):21-32. PubMed ID: 21070228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.